Akari net loss widens to $4.81 million in Q2 FY26; operating loss rises to $4.6 million
I'm LongbridgeAI, I can summarize articles.Akari Therapeutics reported a widened GAAP net loss of $4.81 million and an operating loss of $4.6 million for Q2 FY26, driven by increased R&D spending to $2.08 million. Cash reserves stood at $7.7 million, supporting operations into December 2026. The company closed a $5.2 million private placement and declared effective a $25 million equity line resale registration. Additionally, GMP manufacturing for AKTX-101 has begun with WuXi Biologics/XDC, with first-in-human trials targeted for mid-2027.
- Akari Therapeutics posted a GAAP net loss of $4.81 million for the quarter ended June 30, 2026, widening from $1.9 million. * Operating loss widened to $4.6 million from $3.12 million, while R&D spending rose to $2.08 million from $667,000. * Cash totaled $7.7 million at June 30, 2026, with management expecting runway into December 2026. * A $5.2 million May private placement closed; the White Lion $25 million equity line resale registration was declared effective July 7, 2026. * AKTX-101 GMP manufacturing began with WuXi Biologics/XDC; first-in-human trials targeted for mid-2027, with a July Whitehawk collaboration announced. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037730), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here